GSK3B and myotonic dystrophy type 1: In agreement, the reversion of inactive CUGBP1 into active CUGBP1 with the inhibitors GSK3β, tideglusib or TDZD-8 in the pre-clinical studies in DM1 mice (HSA model) and in DMSXL mice had a positive effect on CNS and neuro-muscular functions [22,23].